Annual SG&A
$6.15 M
-$1.78 M-22.47%
01 July 2024
Summary:
BriaCell Therapeutics annual selling, general & administrative expenses is currently $6.15 million, with the most recent change of -$1.78 million (-22.47%) on 01 July 2024. During the last 3 years, it has risen by +$1.20 million (+24.16%). BCTX annual SG&A is now -22.47% below its all-time high of $7.94 million, reached on 31 July 2023.BCTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.36 M
-$209.50 K-13.33%
01 July 2024
Summary:
BriaCell Therapeutics quarterly selling, general & administrative expenses is currently $1.36 million, with the most recent change of -$209.50 thousand (-13.33%) on 01 July 2024. Over the past year, it has dropped by -$283.30 thousand (-17.21%). BCTX quarterly SG&A is now -62.95% below its all-time high of $3.68 million, reached on 30 April 2021.BCTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$330.27 M
-$4.79 M-1.47%
01 July 2024
Summary:
BriaCell Therapeutics TTM selling, general & administrative expenses is currently -$330.27 million, with the most recent change of -$4.79 million (-1.47%) on 01 July 2024. Over the past year, it has dropped by -$337.70 million (-4542.92%). BCTX TTM SG&A is now -887720.43% below its all-time high of $8.05 million, reached on 31 January 2022.BCTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.5% | -17.2% | -4542.9% |
| 3 y3 years | +24.2% | -3.3% | -5481.8% |
| 5 y5 years | +487.6% | +228.9% | -10000.0% |
BCTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -22.5% | +24.2% | -46.3% | at low | -316.0% | at low |
| 5 y | 5 years | -22.5% | +487.6% | -63.0% | +6482.1% | -519.1% | at low |
| alltime | all time | -22.5% | >+9999.0% | -63.0% | +415.1% | <-9999.0% | at low |
BriaCell Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | $6.15 M(-22.5%) | $1.36 M(-13.3%) | $6.15 M(-16.0%) |
| Apr 2024 | - | $1.57 M(0.0%) | $7.33 M(-3.2%) |
| Jan 2024 | - | $1.57 M(-4.5%) | $7.57 M(+1.9%) |
| Oct 2023 | - | $1.65 M(-35.2%) | $7.43 M(-6.3%) |
| July 2023 | $7.94 M(+9.2%) | $2.54 M(+39.7%) | $7.94 M(+6.3%) |
| Apr 2023 | - | $1.82 M(+26.8%) | $7.46 M(-0.5%) |
| Jan 2023 | - | $1.43 M(-33.3%) | $7.50 M(-6.3%) |
| Oct 2022 | - | $2.15 M(+4.0%) | $8.01 M(+10.2%) |
| July 2022 | $7.27 M(+46.7%) | $2.07 M(+11.4%) | $7.27 M(+16.6%) |
| Apr 2022 | - | $1.85 M(-4.3%) | $6.23 M(-22.6%) |
| Jan 2022 | - | $1.94 M(+37.6%) | $8.05 M(+31.3%) |
| Oct 2021 | - | $1.41 M(+36.9%) | $6.14 M(+23.8%) |
| July 2021 | $4.96 M(+230.7%) | $1.03 M(-72.0%) | $4.96 M(+16.5%) |
| Apr 2021 | - | $3.68 M(>+9900.0%) | $4.26 M(+387.6%) |
| Jan 2021 | - | $20.70 K(-90.9%) | $872.70 K(-35.4%) |
| Oct 2020 | - | $227.50 K(-31.0%) | $1.35 M(-12.2%) |
| July 2020 | $1.50 M(+43.1%) | $329.50 K(+11.7%) | $1.54 M(-3.4%) |
| Apr 2020 | - | $295.00 K(-40.8%) | $1.59 M(-1.8%) |
| Jan 2020 | - | $497.90 K(+20.2%) | $1.62 M(+25.0%) |
| Oct 2019 | - | $414.30 K(+8.2%) | $1.29 M(+17.7%) |
| July 2019 | $1.05 M(-26.1%) | $382.80 K(+18.2%) | $1.10 M(-10.4%) |
| Apr 2019 | - | $323.80 K(+86.1%) | $1.23 M(-17.8%) |
| Jan 2019 | - | $174.00 K(-20.7%) | $1.49 M(-0.8%) |
| Oct 2018 | - | $219.50 K(-57.0%) | $1.51 M(+5.7%) |
| July 2018 | $1.42 M(+61.8%) | $510.60 K(-13.4%) | $1.43 M(+18.3%) |
| Apr 2018 | - | $589.50 K(+216.3%) | $1.20 M(+32.5%) |
| Jan 2018 | - | $186.40 K(+34.5%) | $908.80 K(+1.4%) |
| Oct 2017 | - | $138.60 K(-52.2%) | $896.40 K(+1.3%) |
| July 2017 | $876.20 K(-7.0%) | $289.80 K(-1.4%) | $885.20 K(+443.1%) |
| Apr 2017 | - | $294.00 K(+69.0%) | $163.00 K(+35.3%) |
| Jan 2017 | - | $174.00 K(+36.6%) | $120.50 K(-78.9%) |
| Oct 2016 | - | $127.40 K(-129.5%) | $571.10 K(-5.7%) |
| July 2016 | $942.00 K(-13.0%) | -$432.40 K(-271.9%) | $605.80 K(-42.8%) |
| Apr 2016 | - | $251.50 K(-59.7%) | $1.06 M(-9.5%) |
| Jan 2016 | - | $624.60 K(+285.3%) | $1.17 M(+1.2%) |
| Oct 2015 | - | $162.10 K(+647.0%) | $1.16 M(+10.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2015 | $1.08 M(+270.9%) | $21.70 K(-94.0%) | $1.05 M(-8.4%) |
| Apr 2015 | - | $363.20 K(-40.5%) | $1.15 M(+35.7%) |
| Jan 2015 | - | $610.50 K(+1010.0%) | $844.40 K(+189.5%) |
| Oct 2014 | - | $55.00 K(-53.2%) | $291.70 K(-0.5%) |
| July 2014 | $291.90 K(-0.6%) | $117.50 K(+91.4%) | $293.30 K(+18.9%) |
| Apr 2014 | - | $61.40 K(+6.2%) | $246.60 K(-5.6%) |
| Jan 2014 | - | $57.80 K(+2.1%) | $261.20 K(-5.8%) |
| Oct 2013 | - | $56.60 K(-20.1%) | $277.20 K(-6.1%) |
| July 2013 | $293.80 K(-25.6%) | $70.80 K(-6.8%) | $295.30 K(-1.7%) |
| Apr 2013 | - | $76.00 K(+3.0%) | $300.50 K(-3.9%) |
| Jan 2013 | - | $73.80 K(-1.2%) | $312.80 K(-10.4%) |
| Oct 2012 | - | $74.70 K(-1.7%) | $349.00 K(-17.6%) |
| July 2012 | $395.00 K(-62.4%) | $76.00 K(-13.9%) | $423.70 K(-50.5%) |
| Apr 2012 | - | $88.30 K(-19.7%) | $856.10 K(-14.8%) |
| Jan 2012 | - | $110.00 K(-26.4%) | $1.00 M(-6.9%) |
| Oct 2011 | - | $149.40 K(-70.6%) | $1.08 M(+4.1%) |
| July 2011 | $1.05 M(+225.3%) | $508.40 K(+114.8%) | $1.04 M(+82.3%) |
| Apr 2011 | - | $236.70 K(+28.4%) | $568.70 K(+14.0%) |
| Jan 2011 | - | $184.40 K(+72.0%) | $498.70 K(+36.2%) |
| Oct 2010 | - | $107.20 K(+165.3%) | $366.10 K(+15.9%) |
| July 2010 | $323.30 K(+38.3%) | $40.40 K(-75.8%) | $315.80 K(-24.0%) |
| Apr 2010 | - | $166.70 K(+221.8%) | $415.70 K(+61.2%) |
| Jan 2010 | - | $51.80 K(-9.0%) | $257.90 K(+7.4%) |
| Oct 2009 | - | $56.90 K(-59.4%) | $240.20 K(+2.0%) |
| July 2009 | $233.70 K(+104.8%) | $140.30 K(+1476.4%) | $235.50 K(+55.0%) |
| Apr 2009 | - | $8900.00(-73.9%) | $151.90 K(-11.3%) |
| Jan 2009 | - | $34.10 K(-34.7%) | $171.30 K(+9.3%) |
| Oct 2008 | - | $52.20 K(-7.9%) | $156.70 K(+36.5%) |
| July 2008 | $114.10 K(-11.6%) | $56.70 K(+100.4%) | $114.80 K(+17.7%) |
| Apr 2008 | - | $28.30 K(+45.1%) | $97.50 K(+18.6%) |
| Jan 2008 | - | $19.50 K(+89.3%) | $82.20 K(-23.6%) |
| Oct 2007 | - | $10.30 K(-73.9%) | $107.60 K(-14.5%) |
| July 2007 | $129.10 K(+1401.2%) | $39.40 K(+203.1%) | $125.80 K(+45.6%) |
| Apr 2007 | - | $13.00 K(-71.0%) | $86.40 K(+17.7%) |
| Jan 2007 | - | $44.90 K(+57.5%) | $73.40 K(+157.5%) |
| Oct 2006 | - | $28.50 K | $28.50 K |
| July 2006 | $8600.00 | - | - |
FAQ
- What is BriaCell Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for BriaCell Therapeutics?
- What is BriaCell Therapeutics annual SG&A year-on-year change?
- What is BriaCell Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for BriaCell Therapeutics?
- What is BriaCell Therapeutics quarterly SG&A year-on-year change?
- What is BriaCell Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for BriaCell Therapeutics?
- What is BriaCell Therapeutics TTM SG&A year-on-year change?
What is BriaCell Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of BCTX is $6.15 M
What is the all time high annual SG&A for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual selling, general & administrative expenses is $7.94 M
What is BriaCell Therapeutics annual SG&A year-on-year change?
Over the past year, BCTX annual selling, general & administrative expenses has changed by -$1.78 M (-22.47%)
What is BriaCell Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of BCTX is $1.36 M
What is the all time high quarterly SG&A for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly selling, general & administrative expenses is $3.68 M
What is BriaCell Therapeutics quarterly SG&A year-on-year change?
Over the past year, BCTX quarterly selling, general & administrative expenses has changed by -$283.30 K (-17.21%)
What is BriaCell Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of BCTX is -$330.27 M
What is the all time high TTM SG&A for BriaCell Therapeutics?
BriaCell Therapeutics all-time high TTM selling, general & administrative expenses is $8.05 M
What is BriaCell Therapeutics TTM SG&A year-on-year change?
Over the past year, BCTX TTM selling, general & administrative expenses has changed by -$337.70 M (-4542.92%)